Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vidofludimus calcium - Immunic

Next Previous
X
Search
Drug Profile

Vidofludimus calcium - Immunic

Alternative Names: 4SC-101; IM 90838; IMU 838; SC-12267; VidoCa

Latest Information Update: 16 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator 4SC
  • Developer 4SC; Arizona State University; Immunic; Mayo Clinic
  • Class Amides; Anti-inflammatories; Antivirals; Biphenyl compounds; Carboxylic acids; Cyclopentanes; Fluorobenzenes; Phenyl ethers; Small molecules
  • Mechanism of Action Dihydroorotate dehydrogenase inhibitors; Nuclear receptor subfamily 4 group A member 2 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Multiple sclerosis
  • Phase II/III COVID 2019 infections
  • Phase II Crohn's disease; Post acute COVID 19 syndrome; Ulcerative colitis
  • Discontinued Inflammatory bowel diseases; Primary sclerosing cholangitis; Rheumatoid arthritis; Systemic lupus erythematosus; Transplant rejection

Most Recent Events

  • 18 Sep 2024 Efficacy data from a phase II CALLIPER trial in Multiple sclerosis presented at the 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS-2024)
  • 18 Jul 2024 Phase-II clinical trials in Post-acute-COVID-19-syndrome in Germany (PO) (EudraCT2024-511628-16-00)
  • 28 May 2024 No recent reports of development identified for preclinical development in COVID-2019-infections in USA (PO, Tablet)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top